Related Experiment Video

Updated: Aug 26, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.1K

Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii

Sara Alosaimy1, Taylor Morrisette1, Abdalhamid M Lagnf1

  • 1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State Universitygrid.254444.7, Detroit, Michigan, USA.

Microbiology Spectrum
|October 3, 2022
PubMed

Insights

Eravacycline (ERV) treatment for Acinetobacter baumannii infections, including carbapenem-resistant strains (CRAB), showed a 30-day mortality of 23.9% with few adverse events. This real-world data supports ERV use for challenging Gram-negative infections.

Area of Science:

  • Infectious Diseases
  • Antimicrobial Resistance
  • Clinical Pharmacology

Background:

  • Acinetobacter baumannii, especially carbapenem-resistant strains (CRAB), poses a significant healthcare challenge.
  • Current management guidelines for CRAB infections lack consensus, with recent recommendations favoring minocycline over eravacycline (ERV).

Purpose of the Study:

  • To evaluate the real-world effectiveness and safety of eravacycline (ERV) in patients with Acinetobacter baumannii infections.
  • To provide clinical data on ERV use, particularly for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, addressing a gap in current literature.

Main Methods:

  • A multicenter, real-world cohort study involving 46 patients treated with eravacycline (ERV).
  • Analysis of patient data including infection type, treatment duration, mortality rates, and adverse events.
  • Focus on isolates, with 69.5% identified as carbapenem-resistant Acinetobacter baumannii (CRAB).

Main Results:

  • The study cohort (n=46) primarily had pulmonary infections (58.3%) and received combination therapy (84.4%).
  • Thirty-day mortality was 23.9% overall and 21.9% in the CRAB subgroup.
  • Eravacycline (ERV)-based regimens demonstrated a low incidence of ERV-possible adverse events (2.1%).

Conclusions:

  • Eravacycline (ERV)-based treatment is associated with acceptable outcomes and a low safety profile in a real-world setting for Acinetobacter baumannii infections.
  • This study contributes crucial data supporting the use of eravacycline (ERV) for challenging Gram-negative infections, including CRAB.
  • Findings may inform clinical practice and future guidelines regarding novel tetracycline use in antimicrobial resistance management.
Keywords:
AcinetobacterAcinetobacter baumanniiCRABGram-negative bacteriaeravacyclinehospital infectionstetracyclines

More Related Videos

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System05:06

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

689
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.5K

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
135
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
32
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such...
37
Antibiotic Selection00:57

Antibiotic Selection

Overview
55.0K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
120
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
185